Investment Rating - The investment rating for the company is Neutral (Maintain) with a target price of 12.5 Yuan [2] Core Views - The company reported a total revenue of 6.265 billion Yuan for 2025, a year-on-year decrease of 8.38%, while the net profit attributable to shareholders was 782 million Yuan, an increase of 19.81% year-on-year [2] - The fourth quarter of 2025 saw a revenue of 1.35 billion Yuan, representing a year-on-year increase of 22.20%, and a net profit of -125 million Yuan, which is an improvement from -216 million Yuan in the same period last year [2] - The company is focusing on channel adjustments and new product launches to drive growth, with a target of double-digit revenue growth for 2026 [2][6] Financial Summary - **Revenue and Profit Forecasts**: - 2025A: Revenue 6,265 million Yuan, Net Profit 783 million Yuan - 2026E: Revenue 6,959 million Yuan, Net Profit 862 million Yuan - 2027E: Revenue 7,671 million Yuan, Net Profit 972 million Yuan - 2028E: Revenue 8,449 million Yuan, Net Profit 1,099 million Yuan [2][12] - **Growth Rates**: - Revenue growth rate for 2025 is -8.4%, with expected growth rates of 11.1%, 10.2%, and 10.2% for 2026, 2027, and 2028 respectively [2][12] - Net profit growth rates are projected at 19.8% for 2025, and 10.2%, 12.7%, and 13.1% for the following years [2][12] - **Earnings Per Share (EPS)**: - 2025A: 0.46 Yuan - 2026E: 0.51 Yuan - 2027E: 0.57 Yuan - 2028E: 0.65 Yuan [2][12] - **Valuation Ratios**: - Price-to-Earnings (P/E) ratios are projected at 25, 22, 20, and 18 for the years 2025A to 2028E respectively [2][12] - Price-to-Book (P/B) ratios are expected to be 1.7, 1.8, 1.8, and 1.7 for the same period [2][12] Market Performance - The company’s stock price as of March 20, 2026, is 11.37 Yuan, with a market capitalization of 19.234 billion Yuan [3] - The company has a total share capital of approximately 169.17 million shares, with 112.07 million shares in circulation [3]

Summary of H&H Holdings Conference Call Industry Overview - The global dietary supplement (VDS) market is experiencing steady growth, with a market size of approximately $132.4 billion in 2023 and an annual growth rate of 4%-5% [2][7] - The Chinese health supplement market is growing significantly faster than the global average, with a compound annual growth rate (CAGR) of 8%-9% from 2010 to 2023, increasing from over 70 billion yuan to around 224 billion yuan [2][7] - The health supplement industry in China benefits from aging demographics and new consumption trends, with online sales channels accelerating, rising to 60% post-pandemic [2][9] Company Insights - H&H Holdings has transformed into a health supplement company primarily focused on adult health, with over 90% of Swisse brand revenue coming from online channels, maintaining a market share of 7%-8% [2][11] - The company has diversified its brand matrix by launching new brands targeting teenagers, children, and pets, such as Swisse Me, Little Swisse, and Plus [2][11] - H&H Holdings is actively expanding its oral beauty product line, including high-margin products like super light bottles and anti-sugar pills, which are expected to enhance profitability [2][14] Financial Performance and Projections - H&H Holdings is expected to optimize interest expenses by approximately 100 million yuan in 2025 through the replacement of high-interest dollar debt with domestic low-interest loans, which will directly enhance profits [2][5][21] - The company anticipates an adjusted net profit of around 700 million yuan in 2025, representing a nearly 30% year-on-year growth, indicating a turning point in its fundamentals [2][23] - The company’s revenue structure has shifted, with a 24%-25% decline in milk powder revenue in 2024 due to regulatory changes, but a recovery of 44% in the first quarter of 2025 is expected [2][13][14] Market Strategy and Brand Development - H&H Holdings is focusing on the Southeast Asian market for expansion, aiming to replicate the success of the Swisse brand in this region [2][20][27] - The company’s management team has extensive experience in fast-moving consumer goods (FMCG) and foreign investment, which supports strategic clarity and revenue stability across different phases [2][16] - The Swisse brand has expanded its core family nutrition series to include oral beauty products, which are expected to drive future growth [2][15] Risk Assessment - The company has a high level of goodwill, approximately 7.8 billion yuan, primarily concentrated in the Swisse and pet brands, which are performing well with no significant impairment risks [2][22] - Legal issues are not expected to significantly impact the company's financial status, as past experiences suggest a favorable outcome in similar cases [2][25] Conclusion - H&H Holdings is positioned for significant growth in the health supplement market, with a strong focus on online sales and brand diversification. The company’s financial outlook is positive, with expectations of increased profitability and market expansion, particularly in Southeast Asia. The management's strategic decisions and market positioning provide a solid foundation for future growth [2][26][27]